Global Blood Therapeutics (GBT) broke out to new highs last week and remains strong today. Let's check out the charts of this clinical-stage biopharmaceutical company.
More from Investing
They include not focusing on predicting an exact low and watching for failed bounces.
The result has been a technical breakdown in risk-asset pricing -- and the main culprit is without a doubt, the inability of Congress to compromise.
In the past, investors were often too quick to sell off fast-growing upstarts due to competitive fears. But at current valuations, risks seem to be completely ignored.
Abbott Labs can bring back some normalcy to this country -- and the world -- with its BinaxNOW rapid antigen test along with its amazing Navica app.